CTLA4 and neoplasm: Anti-CTLA-4 antagonist mAb (ipilimumab) does not reduce Treg cell numbers but instead preferentially exclude Tregs from the tumor lesion, so as to increase the intratumoral Teffector/Treg ratio and improve therapeutic efficacy [75, 76].